Samumed has raised $438 million with a $12 billion valuation. Samumed is a leader in medical research and development for tissue-level regeneration. They have a biotechnology platform based on small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology.
One of the primary signaling pathways that regulate the self-renewal and differentiation of adult stem cells is the Wnt pathway, which plays a crucial role in tissue health, ranging from formation to replenishment and from repair to regeneration of various tissues.
Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases.